Regulatory Submission Readiness Checklist: Go/No-Go Gate

A go/no-go readiness gate for regulatory submissions. It helps sponsors distinguish a truly file-ready application from a package that is merely close to complete.

Reviewed by: BioBoston CRO Editorial Team

Infographic summarizing submission readiness gate for clinical trial sponsors.

regulatory submission readiness checklist planning should help the sponsor make a controlled decision, not merely create another document. A go/no-go readiness gate for regulatory submissions. It helps sponsors distinguish a truly file-ready application from a package that is merely close to complete.

Practical principle: Regulatory submission readiness should be judged by unresolved risk, not percent complete. A package can be 98% written and still be a no-go if the remaining 2% changes the regulatory position, core evidence, labeling, or technical validity.

Quick answer: what belongs in the go/no-go gate?

  • Regulatory strategy remains valid.
  • Critical evidence and analyses are final enough for filing.
  • Required documents and forms are complete.
  • Cross-document inconsistencies are resolved.
  • Approvals are documented.
  • Publishing and technical validation are complete.
  • Open issues have explicit acceptance or mitigation.

1. Use Green / Yellow / Red criteria

Status Meaning Action
Green Ready; no unresolved issue materially threatens filing Proceed
Yellow Open issue is bounded, owned, and does not invalidate filing if resolved as planned Proceed conditionally with deadline
Red Open issue could change safety, efficacy, quality, regulatory basis, required content, or technical acceptance Do not file until resolved or formally re-strategized

2. Evidence gate

  • Critical study reports and analyses available.
  • CMC/nonclinical/clinical source versions controlled.
  • Data cutoffs aligned across dependent documents.
  • Known limitations and inconsistencies have a documented regulatory interpretation.

3. Content and consistency gate

  • Application content inventory reconciled.
  • Key numbers, dates, populations, doses, and claims agree across documents.
  • Meeting commitments and prior authority feedback are addressed.
  • Labeling or indication language matches the evidence and pathway.

4. Technical gate

  • File naming, formats, placement, and metadata conform to current technical requirements.
  • Hyperlinks/bookmarks and references work.
  • Submission validation has been run and errors resolved.
  • Transmission roles and backup plan are confirmed.

5. Decision record

Question Decision
What is still open? List only issues that could affect filing or review
Who owns it? One accountable owner
By when? Resolution deadline before or after filing
Can FDA review without it? Document rationale
What happens if assumption is wrong? Define contingency

6. Red flags

  • “We can explain it if FDA asks” is being used for a known material inconsistency.
  • Final numbers differ across summary documents.
  • Late changes bypass targeted re-review.
  • Publishing validation is treated as a same-day task.
  • No one owns FDA information requests after transmission.

Need an independent readiness gate?

BioBoston CRO Submission Planning can help run a structured readiness assessment and convert open items into a controlled go/no-go decision.

For sponsors that need hands-on support applying this framework, BioBoston CRO Submission Planning can support the underlying regulatory and cross-functional work.

Related Resources

START A CONVERSATION

Tell Us What Support You Need

Select the support you need and share a few details about your project. We’ll use this information to route your inquiry to the appropriate BioBoston team member.


Please do not submit confidential, patient-identifiable, or proprietary information through this form.